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Abstract Fusion proteins were constructed between the porcine
K2A-adrenoceptor and either wild-type (Cys351) or a pertussis
toxin-resistant (Gly351) form of the G protein Gi1K. Addition of
adrenaline to membranes expressing the fusion proteins resulted
in concentration-dependent stimulation of their high affinity
GTPase activity. The K2A-adrenoceptor-wild type Gi1K fusion
protein produced substantially higher maximal stimulation of
GTPase activity in response to adrenaline than that containing
Gly351 Gi1K. Treatment of the fusion proteins as agonist-
regulated enzymes allowed measurement of Vmax and turnover
number for adrenaline-stimulation of the GTPase activity of
each fusion construct. The turnover number of the K2A-
adrenoceptor-Cys351Gly Gi1K fusion protein was only 44% of
that for the K2A-adrenoceptor-wild type Gi1K fusion protein.
These data provide the first direct quantitative evaluation of the
effects of a mutation of a G protein on the capacity of an agonist-
occupied receptor to activate the mutant.
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1. Introduction
The K subunits of members of the Gi-like family of hetero-
trimeric G proteins share the common feature of acting as
substrates for ADP-ribosylation catalysed by pertussis toxin
[1]. This is due to the presence of a conserved cysteine residue
(Cys351 in Gi1K) 4 amino acids from the C-terminus of these G
proteins. Pertussis toxin-catalysed ADP-ribosylation prevents
e¡ective information transfer from appropriate receptors to
the Gi-like G proteins [1]. Mutagenic alteration of this residue
prevents pertussis toxin-catalysed ADP-ribosylation and, as
certain mutations (e.g. Gly, Ser) have been reported to pre-
serve receptor coupling, such modi¢ed G proteins have been
used to examine the speci¢city of receptor interactions with
di¡erent Gi-family G proteins [2^8]. Despite this, analysis of
the quantitative e¡ects of such mutations has not been con-
sidered. We have recently taken a novel approach to examine
the details of interactions between receptors and G proteins.
Following the initial demonstration that a fusion protein gen-
erated between the L2-adrenoceptor and the K subunit of Gs
could activate adenylyl cyclase in an agonist-dependent man-
ner [9] we generated an equivalent fusion protein between the
porcine K2A-adrenoceptor and a pertussis toxin-insensitive
(Cys351Gly) mutant of Gi1K [10^12]. This resulted in expres-
sion of a single polypeptide containing both functions [10^12].
We demonstrated the utility of such an approach by measur-
ing the capacity of this fusion protein to function as an ago-
nist-activated GTPase following pertussis toxin treatment of
cells [10^12]. Furthermore, fusion proteins between the recep-
tor and acylation-resistant, mutationally modi¢ed forms of
Gi1K which could not reach the plasma membrane when ex-
pressed independently, resulted in rescue of agonist activation
of these G protein mutants [11]. Importantly for quantitative
analyses, the fusion protein strategy de¢nes a 1:1 stoichiom-
etry of expression of the elements of the fusion protein and
that they must be in proximity following expression [11]. Nei-
ther of these features can be easily de¢ned and controlled
during simple co-transfection experiments.
Potentially, the fusion protein approach should be particu-
larly suitable to examine the e¡ects of minor mutations in
receptor or G protein which may alter their interactions.
Herein we use this strategy to examine the quantitative e¡ects
of alteration of the pertussis toxin-sensitive cysteine351 of Gi1K
to glycine on the capacity of the G protein to be activated by
the K2A-adrenoceptor.
2. Materials and methods
2.1. Materials
All materials for tissue culture were supplied by Life Technologies,
Inc. (Paisley, Strathclyde, Scotland, UK). [3H]RS-79948-197 (90 Ci/
mmol) was purchased from Amersham International. [Q-32P]GTP
(30 Ci/mmol) was obtained from DuPont/NEN. Pertussis toxin
(240 Wg/ml) was purchased from Speywood. All other chemicals
were from Sigma or Fisons plc and were of the highest purity avail-
able. Oligonucleotides were purchased from Genosys (Cambridge,
UK).
2.2. Construction of the K2A-adrenoceptor-Cys351Gi1K fusion construct
The porcine K2A-adrenoceptor [13] was obtained from Dr. L.E.
Limbird, Vanderbilt University, TN, USA. Rat Cys351GlyGi1K was
linked to the K2A-adrenoceptor as described previously to generate
K2AR-Cys351GlyGi1K [10] and ligated into the KpnI and EcoRI sites
of the eukaryotic expression vector pcDNA3 (Invitrogen). Wild-type
(Cys351) rat Gi1K cDNA in pcDNA3 was digested with the restriction
enzymes SacII and EcoRI. This 1.3-kb fragment was recovered and
ligated with K2AR-Cys351GlyGi1K in pcDNA3 from which the equiv-
alent 1.3-kb SacII-EcoRI fragment had been removed. This generated
K2AR-Cys351Gi1K in pcDNA3.
2.3. Cell culture and transfection
COS-7 cells were maintained in DMEM containing 10% (v/v) foetal
calf serum, 2 mM L-glutamine, 100 units/ml penicillin and 100 Wg/ml
streptomycin. Cells were seeded in 60-mm culture dishes and grown to
60^80% con£uency (18^24 h) prior to transfection with pCDNA 3 con-
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taining the relevant cDNA species using lipofectamine reagent (Life
Technologies, Inc.) [10]. For transfection, 2.5^2.8 Wg of DNA was
mixed with 10 Wl of lipofectamine in 0.2 ml of Opti-MEM (Life
Technologies, Inc.) and incubated at room temperature for 30 min
prior to the addition of 1.8 ml of Opti-MEM. COS-7 cells were ex-
posed to the DNA-lipofectamine mixture for 5 h. Two ml of 20% (v/v)
foetal calf serum in DMEM was then added to the cells. Cells were
harvested 48 h after transfection. In a number of experiments cells
were treated for the ¢nal 24 h prior to cell harvest with pertussis toxin
(between 25^200 ng/ml in di¡erent experiments).
2.4. Preparation of membranes
Plasma membrane-containing P2 particulate fractions were pre-
pared from cell pastes that had been stored at 380‡C following har-
vest as described previously [14].
2.5. [3H]RS-79948-197 binding studies
Binding assays were initiated by the addition of 2^4 Wg of protein to
an assay bu¡er (10 mM Tris-HCl, 50 mM sucrose, 20 mM MgCl2, pH
7.5) containing [3H]RS-79948-197 [15] (0^1 nM). Non-speci¢c binding
was determined in the presence of 100 WM idazoxan. Reactions were
incubated at 30‡C for 45 min, and bound ligand was separated from
free by vacuum ¢ltration through GF/C ¢lters. The ¢lters were
washed with 3U5 ml of assay bu¡er, and bound ligand was estimated
by liquid scintillation spectrometry.
2.6. High a⁄nity GTPase assays
High a⁄nity GTPase assays were performed as described in [10,12].
Non-speci¢c GTPase was assessed by parallel assays containing 100
WM GTP.
All experiments were performed on at least three membrane prep-
arations derived from di¡erent transient transfections. Because levels
of expression of the fusion proteins varied between the individual
transfections over a greater than 2-fold range the data from individual
experiments was pooled only when presenting GTPase activity meas-
urements as turnover number (see Table 1).
3. Results
Fusion proteins were generated between the porcine K2A-
adrenoceptor and wild type rat Gi1K to generate K2AR-Gi1K
or with a pertussis toxin-resistant, Cys351Gly, mutant of Gi1K
to generate K2AR-Cys351GlyGi1K by attachment of the N-ter-
minus of the G protein to the C-terminus of the receptor.
These proteins were expressed transiently in COS-7 cells. Sat-
uration speci¢c binding studies using the K2-adrenoceptor an-
tagonist [3H]RS-79948-197 were performed routinely on mem-
branes from these cells to ascertain levels of expression of the
constructs (Fig. 1). The alteration in sequence at the C-termi-
nus of the fusion protein did not alter the a⁄nity of binding
of the [3H]ligand, Kd at K2AR-Gi1K= 0.30 þ 0.05 nM, n = 4, Kd
at K2AR-Cys351GlyGi1K= 0.39 þ 0.12 nM, n = 10, means þ
S.D., P = 0.17.
Basal high a⁄nity GTPase activity and its stimulation by a
range of concentrations of adrenaline was then measured in
membranes expressing K2AR-Gi1K using 0.5 WM GTP as sub-
strate. Adrenaline produced a concentration-dependent in-
crease in high a⁄nity GTPase activity with an EC50 of
1.6 þ 0.2U1037 M (mean þ S.E.M., n = 3) (Fig. 2). Equivalent
experiments on membranes expressing (K2AR-Cys351GlyGi1K)
also resulted in a concentration-dependent increase in high
a⁄nity GTPase activity but now the EC50 for adrenaline
was higher (1.7 þ 0.2U1036 M, mean þ S.E.M., n = 3,
P = 0.0014) (Fig. 2). Expression of the two fusion proteins
to similar levels in COS-7 cell membranes (Fig. 1) resulted
in a substantially higher maximal stimulation of high a⁄nity
GTPase activity by adrenaline at K2AR-Gi1K compared to
K2AR-Cys351GlyGi1K (Fig. 2). To examine this more exten-
sively the fusion proteins were treated as agonist-activated
enzymes and basal and adrenaline (100 WM)-stimulated high
a⁄nity GTPase activity measured at varying [GTP] (Fig. 3).
Analysis of such data demonstrated the adrenaline-stimulated
Vmax of K2AR-Gi1K to be substantially greater than K2AR-
Cys351GlyGi1K (Fig. 3) whereas the Km for GTP (K2AR-
Gi1K=0.42 þ 0.14 WM, K2AR-Cys351GlyGi1K= 0.43 þ 0.16 WM,
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Table 1
Comparison of the adrenaline-stimulated turnover number of K2AR-
Gi1K and K2AR-Cys351GlyGi1K
Turnover number (min31)
K2AR-Gi1K 8.0 þ 0.6
K2AR-Cys351GlyGi1K 3.5 þ 0.7
Turnover numbers (means þ S.E.M., n = 4) for adrenaline-stimulated
GTPase activity were calculated at Vmax from experiments similar to
those displayed in Figs. 3 and 5 and saturation 3H-antagonist binding
data performed on the same membrane preparations. The contribu-
tion of endogenous G proteins to the total high a⁄nity GTPase signal
was subtracted as de¢ned in Section 3.
Fig. 1. Binding of [3H]RS-79948-197 to K2AR-Gi1K and K2AR-
Cys351GlyGi1K. The speci¢c binding of [3H]RS-79948-197 to mem-
branes of COS-7 cells expressing either K2AR-Gi1K (upper) or K2AR-
Cys351GlyGi1K (lower) was assessed following transient transfection
of their cDNAs. Insets represent Scatchard transformation of the
data. Equivalent analyses were performed on all the individual tran-
sient transfections used in the study. Levels of expression varied
over a greater than 2-fold range in the individual transfections.
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mean þ S.D., n = 4 in each case) was not di¡erent for the two
constructs (P = 0.94).
Prior pertussis toxin (25 ng/ml, 24 h) treatment of COS-7
cells is su⁄cient to cause complete ADP-ribosylation of en-
dogenously expressed Gi-like G proteins and to fully attenu-
ate agonist stimulation of high a⁄nity GTPase activity by a
transiently expressed K2A-adrenoceptor [16]. Such pretreat-
ment of COS-7 cells expressing K2AR-Gi1K resulted in a sub-
stantial (67.7 þ 2.4%, mean þ S.E.M., n = 3), but not complete,
reduction in the capacity of adrenaline to stimulate high af-
¢nity GTPase activity which was accompanied by a small
(5.1-fold) but statistically signi¢cant (P = 0.04) increase in
the EC50 for adrenaline (Fig. 4, upper panel). Although
such treatment did not abolish adrenaline stimulation of
high a⁄nity GTPase activity, pretreatment of the cells with
higher levels of pertussis toxin (up to 200 ng/ml, 24 h) pro-
duced no further reduction in the response to adrenaline (data
not shown). As such, the remaining agonist-stimulated
GTPase activity is unlikely to simply re£ect a requirement
for higher levels of the toxin to modify wild-type Gi1K within
the fusion protein.
Equivalent pertussis toxin pretreatment of cells expressing
K2AR-Cys351GlyGi1K did not alter agonist-stimulated GTPase
activity substantively (Fig. 4, lower panel) and did not alter
the EC50 for adrenaline (2.0 þ 0.5U1036 M, mean þ S.E.M.,
n = 3, P = 0.64).
Adrenaline-stimulated GTPase activity vs. [GTP] experi-
ments equivalent to those detailed in Fig. 3 con¢rmed both
that pertussis toxin pretreatment had little apparent e¡ect on
the agonist-stimulated Vmax of K2AR-Cys351GlyGi1K (Fig. 5,
upper panel). In contrast such treatment substantially re-
duced, but did not abolish, agonist-stimulated GTPase activ-
ity of K2AR-Gi1K when measured at Vmax (Fig. 5, lower panel)
again without altering the Km for GTP (following pertussis
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Fig. 2. Adrenaline stimulates the GTPase activity of K2AR-Gi1K to
a greater extent than K2AR-Cys351GlyGi1K. Basal high a⁄nity
GTPase activity and its regulation by varying concentrations of
adrenaline were measured using 0.5 WM GTP in membranes of
COS-7 cells expressing either K2AR-Gi1K (¢lled symbols) or K2AR-
Cys351GlyGi1K (open symbols). Data is derived from the same set
of membranes displayed in Fig. 1 and is representative of 4 separate
experiments performed on membranes from di¡erent sets of trans-
fections.
Fig. 3. Adrenaline increases the Vmax of the GTPase activity of
K2AR-Gi1K to a greater extent than K2AR-Cys351GlyGi1K although
their Km for GTP is not di¡erent. Basal high a⁄nity GTPase activ-
ity (open symbols) and its stimulation by adrenaline (100 WM) was
measured at a range of concentrations of GTP in membranes
of COS-7 cells expressing either K2AR-Gi1K (circles) or K2AR-
Cys351GlyGi1K (triangles). The data are presented as an Eadie-
Hofstee transformation.
Fig. 4. The e¡ect of pertussis toxin on adrenaline stimulation of the
GTPase activity of K2AR-Gi1K and K2AR-Cys351GlyGi1K. Basal high
a⁄nity GTPase activity and its regulation by varying concentrations
of adrenaline was measured using 0.5 WM GTP in membranes from
either untreated (open symbols) or pertussis toxin pretreated (25 ng/
ml, 24 h) COS-7 cells transiently transfected to express K2AR-Gi1K
(upper panel) or K2AR-Cys351GlyGi1K (lower panel).
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toxin treatment K2AR-Gi1K= 0.39 þ 0.11 WM, mean þ S.D.,
P = 0.1).
Levels of expression of the receptor-G protein fusion pro-
teins varied between individual transfections and thus trans-
lated into di¡erences in absolute levels of agonist-stimulated
GTPase activity in di¡erent membrane preparations (note the
variation in absolute GTPase activity numbers in the di¡erent
experiments displayed). Therefore, data from experiments
such as those in Figs. 3 and 5 were converted to adrenaline-
induced GTPase turnover numbers (GTPase activity at Vmax
(pmol GTP hydrolysed/min/mg membrane protein)/fusion
protein expression levels (pmol/mg membrane protein) (Table
1). This demonstrated unequivocally the greater capacity of
adrenaline to stimulate the GTPase activity of K2AR-Gi1K
compared to K2AR-Cys351GlyGi1K. However, when presented
in this manner, although the measured GTPase turnover num-
ber for K2AR-Gi1K was reduced from 9.7 þ 0.6 min31 to
2.9 þ 0.3 min31 by pertussis toxin treatment there was also a
reduction from 5.6 þ 0.5 min31 to 4.4 þ 0.5 min31 in the ad-
renaline-stimulated turnover number of K2AR-Cys351GlyGi1K
following pertussis toxin treatment (means þ S.E.M., n = 4 in
each case). As K2AR-Cys351GlyGi1K is resistant to pertussis
toxin treatment this contribution to the overall GTPase signal
must re£ect activation of the endogenously expressed pertus-
sis-sensitive G proteins (see Section 4 for details). This con-
tribution was thus subtracted to allow direct comparison of
turnover number of K2AR-Gi1K and K2AR-Cys351GlyGi1K in
response to adrenaline and thus a direct measurement of
the maximal capacity (44%) of the adrenaline-occupied K2A-
adrenoceptor to active Gly351Gi1K compared to wild type
(Cys351)Gi1K (Table 1).
4. Discussion
Minor mutations in both receptors and G proteins are
known which interfere with functional contacts between these
proteins. A good example of this is the unc mutation of GsK
in which alteration of Arg389 to Pro, six amino acids from the
C-terminal of the protein, prevents functional activation of
the G protein by an agonist-occupied L-adrenoceptor. The
deleterious e¡ects of such a mutation can easily be considered
when it is appreciated that the C-terminal region of G protein
K subunits represents a key interaction domain for receptors
and this speci¢c mutation is likely to produce a marked struc-
tural deformation in this region. Pertussis toxin, elucidated by
Bordetella pertussis, attenuates functional contacts between
receptors and the Gi-family of G proteins because it functions
as an ADP-ribosyltransferase, the acceptor for which is a
conserved cysteine residue 4 amino acids from the C-terminus
of these G proteins [1]. Because of this capacity of pertussis
toxin and the routine co-expression of a number of pertussis
toxin-sensitive G-proteins by most cells, a number of groups
have generated mutants of the Gi-proteins which have been
used to examine potential selectivity of interactions between
receptors and individual Gi-G proteins. Such studies have
used alterations of the pertussis toxin-sensitive Cys to either
Ser or Gly, presumably as these have been considered con-
servative mutations which might not interfere dramatically
with function. However, in studies on the interaction of rho-
dopsin and transducin, a combinatorial library of peptides
derived from the C-terminal region of transducin has sug-
gested the absolute importance of the presence of the pertussis
toxin-sensitive Cys for high a⁄nity interactions [17] whereas
direct mutational alterations of the protein have suggested
greater £exibility, with a Cys-Ala mutation having little e¡ect
[18] and a Cys-Tyr mutant resulting in complete loss of func-
tion [19]. The rhodopsin-transducin system has a range of
speci¢c features which make such assays relatively easy to
perform, including a capacity to measure the stabilisation of
meta-rhodopsin II spectrophotometrically. However, despite
the many features of commonality between rhodopsin-trans-
ducin and the interactions of other receptor and G protein
pairs, there is no a priori reason to assume that such muta-
tional data can be directly compared.
Available studies utilising co-expression of a receptor with
mutationally modi¢ed Gi-like G proteins which have rendered
them insensitive to pertussis toxin [2^8] have not been de-
signed to provide quantitative analysis of the e¡ects of the
mutation. Therefore, we have taken the strategy of utilising
fusion proteins [9^12] in which a receptor is linked to each of
the wild-type and mutated G protein to provide such quanti-
tation. The basis for this approach is three-fold. (i) The nature
of the fusion proteins de¢ned that the stoichiometry of recep-
tor and G protein is ¢xed as 1:1. This would be di⁄cult to
achieve in most other systems and eliminates concerns that the
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Fig. 5. The e¡ect of pertussis toxin on the Vmax of the GTPase ac-
tivity of K2AR-Gi1K and K2AR-Cys351GlyGi1K. Basal high a⁄nity
GTPase activity (open symbols) and its stimulation by adrenaline
(100 WM) (¢lled symbols) were measured at a range of concentra-
tions of GTP in membranes of COS-7 cells expressing either K2AR-
Cys351GlyGi1K (upper) or K2AR-Gi1K (lower) which were untreated
(circles) or pretreated with pertussis toxin (25 ng/ml, 24 h) (trian-
gles). The data are presented as Eadie-Hofstee transformations.
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mutation in the G protein might signi¢cantly alter its state
level of expression. This strategy also allowed absolute quan-
titation of expression of the proteins from saturation 3H-an-
tagonist ligand binding studies. (ii) The nature of the fusion
proteins de¢nes that the receptor and G protein must be in
proximity following expression. Again there is no inherent
reason to assume this is the case in co-transfection studies.
Mutational alteration of the G protein may alter this as we
and others have demonstrated for acylation mutations of G
proteins [20^23]. On this basis we have previously used a
fusion protein strategy to ascertain whether acylation is inte-
gral to signal transduction from receptor to G protein or
simply required to target the G protein appropriately to the
membrane [11]. (iii) Using the fusion proteins, agonist-acti-
vated GTPase activity can be converted to enzyme catalytic
centre activity and thus provide a direct measure of activation.
Using this approach we have demonstrated herein
that the adrenaline-stimulated turnover number of K2AR-
Cys351GlyGi1K is only 44% of that of K2AR-Gi1K when meas-
ured at Vmax using a maximally e¡ective concentration of
adrenaline. There was no di¡erence, however, in the Km for
GTP (Fig. 3). These are unique sets of measurements and
could not have been calculated without development of the
fusion protein strategy.
A number of elements of the study deserve further com-
ment. Pertussis toxin treatment of K2AR-Gi1K expressing
COS-7 cells did not result in complete ablation of adrena-
line-stimulated GTPase activity, even when using 10-fold
higher concentrations of the toxin than we have previously
demonstrated to be required to fully attenuate GTPase stim-
ulation in membranes of these cells by the expressed, sepa-
rated, K2A-adrenoceptor [16]. Indeed, at Vmax some 30% of the
total adrenaline-stimulated function was resistant to pertussis
toxin treatment. Although we have recently shown the ca-
pacity of K2AR-Cys351GlyGi1K to activate both endogenously
expressed Gi and the fusion protein partner G protein follow-
ing stable expression of this construct in Rat 1 ¢broblasts [24],
the pertussis toxin resistant fraction of activity cannot result
from interaction with endogenous Gi as this was fully ADP-
ribosylated by the toxin treatment (data not shown). The most
obvious explanation for this data is that addition of ADP-
ribose to Cys351 of Gi1K within the con¢nes of the fusion
protein is simply insu⁄cient to fully prevent adrenaline-medi-
ated GDP-GTP exchange and subsequent hydrolysis, even
though this is generally held to be true for interactions be-
tween the separated receptor and G protein [1]. A second
possibility is that the conformation of the receptor-G protein
fusion protein is such that a fraction of the fusion protein
population was shielded from ADP-ribosylation catalysed by
pertussis toxin. Although this possibility cannot be ¢rmly ex-
cluded, the lack of further reduction of the e¡ects of adrena-
line following treatment with between 25^200 ng/ml pertussis
toxin does not favour a concept of simple variation in toxin
e⁄ciency. Residual agonist-activated GTPase activity is not
uncommon in situations in which all of the measurable Gi-
G protein has become ADP-ribosylated. Such observations
are often taken to imply interaction of the receptor with fur-
ther, pertussis toxin-insensitive, G proteins but this view is
rarely tested directly. Certainly, expression of the isolated
porcine K2A-adrenoceptor in COS-7 cells at substantially high-
er levels than used herein for the fusion proteins does not
result in noticeable stimulation of GTPase activity following
pertussis toxin treatment [16]. Such results suggest that any
interactions with other classes of G proteins could not have
been detected with this assay.
Although the data of Figs. 4 and 5 seem to indicate that
pertussis toxin treatment had no measurable e¡ect on adrena-
line-stimulated GTPase activity on COS-7 cells membranes
expressing K2AR-Cys351GlyGi1K this is not strictly true.
Although no more than a 20% e¡ect, there were consistently
somewhat higher steady-state levels of K2AR-Cys351GlyGi1K in
the samples treated with pertussis toxin compared to vehicle
treated controls. Therefore, in calculations of adrenaline-in-
duced turnover number (Table 1), this was lower in pertussis
toxin treated COS-7 cells expressing K2AR-Cys351GlyGi1K (see
Section 3) even though this construct cannot be modi¢ed by
the toxin. The obvious conclusion is that in this system the
pertussis toxin-sensitive contribution to the total adrenaline-
stimulated GTPase must be provided by interactions between
the K2AR-Cys351GlyGi1K fusion protein and endogenous Gi.
As such, these values were subtracted, as were equivalent val-
ues from the data with K2AR-Gi1K, to allow absolute turnover
numbers to be calculated for the two fusion proteins. It is
noteworthy that the K2AR-Gi1K protein also maintained a
10-fold lower EC50 for adrenaline than K2AR-Cys351GlyGi1K,
a feature we have also noted following individual co-expres-
sion of the K2A-adrenoceptor and the wild-type and Cys351Gly
forms of Gi1K [16].
Many assay systems for agonist ligands at G protein-
coupled receptors utilise G protein activation assays based
on either agonist-enhancement of GTPase activity or of the
binding of ligands such as [35S]GTPQS [25^29]. The current
studies provide an entirely novel approach to examine the
quantitative details of alterations in receptor-G protein inter-
actions which should be equally amenable to mutations in
both receptor or G protein.
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